Taylor et al. Approaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active disease. BMC Med

Al-Attar et al. Multidisciplinary paper on patient blood management in cardiothoracic surgery in the UK: perspectives on practice during COVID-19. J Cardiothoracic Surg

Ariceta et al. ePHex: a phase 3, double-blind, placebo-controlled, randomized study to evaluate long-term efficacy and safety of Oxalobacter formigenes in patients with primary hyperoxaluria. Pediatric Nephrol

Mundy et al. Association for Human Pharmacology in the Pharmaceutical Industry conference 2022: impending change, innovations and future challenges.Front Pharmacol

Al-Attar, N., Gaer, J., Giordano, V. et al. Multidisciplinary paper on patient blood management in cardiothoracic surgery in the UK: perspectives on practice during COVID-19. J Cardiothorac Surg 18, 96 (2023).

Taylor et al. Approaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active disease. BMC Medicine

Reid H., et al. Evaluation of NTP42, a novel thromboxane receptor antagonist, in a first-in-human phase I clinical trial. Frontiers in Pharmacology

Davies et al. Lipidome Analysis in Brain and Peripheral Plasma Following Milk Fat Globule Membrane Supplementation in Rodents. Mol Nutr Food Res

Smith and Matthews. Aromatic ointments for the common cold: what does the science say? Drugs Context

Gritsova et al. Azoximer Bromide: Mystery, Serendipity, and Promise. Front Oncol

Milliner et al. Plasma oxalate and eGFR are correlated in primary hyperoxaluria patients with maintained kidney function—data from three placebo-controlled studies. Pediatric Nephrol

Hoppe et al. Effects of Oxalobacter formigenes in subjects with primary hyperoxaluria Type 1 and end-stage renal disease: a Phase II study. Nephrol Dial Transplant

Monk et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial.Lancet Respir Med

Santeramo et al . Vector Copy Distribution at a Single-Cell Level Enhances Analytical Characterization of Gene-Modified Cell Therapies. Mol Ther Methods Clin Dev

P. Kumar, J. Leider, J. Slim, G. Moyle, M. Leonard, R.B. Cash, S. Weinheimer, P. Mesquita. Disease Severity Impact on Long-Term Virologic Response to Ibalizumab In Expanded Access Protocol (Tmb-311)

H. Jullien, M. Leonard, R.B. Cash, P. Mesquita, S. Weinheimer, C. Marsolais Assessment of Genotypic Patterns Associated with HIV-1 Sensitivity to Ibalizumab

Bolger et al. Evaluation of an increased strut porosity silicate‐substituted calcium phosphate, SiCaP EP, as a synthetic bone graft substitute in spinal fusion surgery: a prospective, open‐label study. Eur Spine J

Harrison et al. Increasing the incidence of drain‐free day‐case mastectomies with the use of a fibrin tissue sealant; data from a single surgical center in the United Kingdom. Breast J

Mokawem et al. Lumbar interbody fusion rates with 3D-printed lamellar titanium cages using a silicate-substituted calcium phosphate bone graft. J Clin Neuriscience

Coughlan et al. Coughlan et al. A Prospective, Randomized, Multicenter Study Comparing Silicated Calcium Phosphate versus BMP-2 Synthetic Bone Graft in Posterolateral Instrumented Lumbar Fusion for Degenerative Spinal Disorders. Spine

Fellström et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet

Zeitlinger et al. Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid. J Antimicrob Chemother

Emmanual et al. Constipation in older people: A consensus statement. Int J Clinical Practice

Berlin et al. EP3/FP dual receptor agonist ONO-9054 administered morning or evening to patients with open-angle glaucoma or ocular hypertension: results of a randomised crossover study. Br J Ophthalmol

Everson et al. Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection. Annals Intern Med

Lawitz et al. A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1–4 hepatitis C virus. Journal of Viral Hepatitis

Molina et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet

Planko et al. Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection. Annals Int Med

Smucker et al. Assessment of sicap-30 in a rabbit posterolateral fusion model with concurrent chemotherapy. The Iowa Orthopaedic Journal

Eastell et al. Morning vs evening dosing of the cathepsin K inhibitor ONO-5334: effects on bone resorption in postmenopausal women in a randomized, phase 1 trial. Osteoporos Int

Suto et al. Safety,Tolerability,and Pharmacokinetic Profile of the Novel Translocator Protein 18kDa Antagonist ONO-2952 in Healthy Volunteers. Clin Therap

Vidall et al. Impact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: a cross-sectional multinational survey. Supportive Care in Cancer

Eastell et al. Effect of ONO‐5334 on Bone Mineral Density and Biochemical Markers of Bone Turnover in Postmenopausal Osteoporosis: 2‐Year Results From the OCEAN Study. J Bone Mineral Res

Follows et al. Efficacy, safety and tolerability of GS K2190915, a 5-lipoxygenase activating protein inhibitor, in adults and adolescents with persistent asthma: a randomised dose-ranging study. Resp Res

Liu et al. A Single and Multiple Dose Study to Investigate the Pharmacokinetics of a Prolonged Release Formulation of Ropinirole in Healthy Chinese Subjects. Clin Pharmacol Drug Development

Zhang et al. The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson’s disease: A multicenter, double-blind, randomized, placebo-controlled study. Parkinsonism and Related Disorders

Snowise et al. Addition of a 5-lipoxygenase-activating protein inhibitor to an inhaled corticosteroid (ICS) or an ICS/long-acting beta-2-agonist combination in subjects with asthma. Current Med Res Opin

Lopez et al. Eight weeks of supplementation with a multi-ingredient weight loss product enhances body composition, reduces hip and waist girth, and increases energy levels in overweight men and women. J Int Soc Sports Nut

Berges et al. Pharmacokinetics, Safety, and Tolerability Following the Administration of a Single Dose of a Combination Tablet Containing Sumatriptan and Naproxen Sodium in Adolescent Patients With Migraine and in Healthy Adult Volunteers. Clin Pharmacol Drug Develop

Hocher et al. Renal and Cardiac Effects of DPP‑4 Inhibitors – from Preclinical Development to Clinical Research. Kidney Blood Press Res

Cameron et al. Directed osteogenic differentiation of human mesenchymal stem/ precursor cells on silicate substituted calcium phosphate. J Biomed Mater Res Part A

Denning et al. Pharmacokinetics, Safety, and Tolerability of GS-9851, a Nucleotide Analog Polymerase Inhibitor for Hepatitis C Virus, following Single Ascending Doses in Healthy Subjects. Antimicrob. Agents Chemother

Lawitz et al. Pharmacokinetics, Pharmacodynamics, and Tolerability of GS-9851, a Nucleotide Analog Polymerase Inhibitor, following Multiple Ascending Doses in Patients with Chronic Hepatitis C Infection. Antimicrob Agents Chemother

Emtestam et al. Treatment of distal subungual onychomycosis with a topical preparation of urea, propylene glycol and lactic acid: results of a 24-week, double-blind, placebo-controlled study. Mycoses

Faergemann. Kerasal nail clinical studies demonstrate early visible improvement in nails damaged by onychomycosis. Podiatry Management

Guth et al. Effects of serum protein on ionic exchange between culture medium and microporous hydroxyapatite and silicate-substituted hydroxyapatite. J Mater Sci: Mater Med

Campion et al. Increasing strut porosity in silicate-substituted calcium-phosphate bone graft substitutes enhances osteogenesis. J Biomed Mat Res B: APPLIED BIOMATERIALS

Esser et al. Efficacy, adherence and tolerability of once daily tenofovir df-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: results of a 48-week open-label study. Eur J Med Res

Daley-Yates and Parkins. Establishing bioequivalence for inhaled drugs; weighing the evidence. Expert Opin Drug Deliv

Lister et al. Pharmacokinetics, Safety, and Tolerability of Ascending Doses of Sublingual Fentanyl, With and Without Naltrexone, in Japanese Subjects. J Clin Pharmacol

Faergemann et al. Early and Visible Improvements after Application of K101 in the Appearance of Nails Discoloured and Deformed by Onychomycosis. J Cosmetics, Dermatol Sci Applications

Lopez. Choosing the right Omega-3 supplement: Natural Triglyceride Omega-3 versus Synthetic Ethyl Ester Intelligenttabs.

Guth et al. Surface Physiochemistry Affects Protein Adsorption to Stoichiometric and Silicate-Substituted Microporous Hydroxyapatites. ADV ENG MATERIALS

Guth et al. Effect of Silicate-Substitution on Attachment and Early Development of Human Osteoblast-Like Cells Seeded on Microporous Hydroxyapatite Discs. Adv Eng Mat

Campion et al. Increasing strut porosity in silicate-substituted calcium-phosphate bone graft substitutes enhances osteogenesis. J Biomed Materials Res J

Lister et al. Pharmacokinetics, Safety, and Tolerability of Ascending Doses of Sublingual Fentanyl, With and Without Naltrexone, in Japanese Subjects. J Clin Pharmacol

Valecha et al. An Open-Label, Randomised Study of Dihydroartemisinin-Piperaquine Versus Artesunate-Mefloquine for Falciparum Malaria in Asia. PLoS ONE

Fuchs et al. Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans. J Pharmacy Pharmacol

Rungby. Inhibition of dipeptidyl peptidase 4 by BI-1356, a new drug for the treatment of beta-cell failure in type 2 diabetes. Expert Opin Investig Drugs

Klein et al. The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis. Liver Int

Thomas et al. Chronic Treatment with the Dipeptidyl Peptidase-4 Inhibitor BI 1356 [(R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] Increases Basal Glucagon-Like Peptide-1 and Improves Glycemic Control in Diabetic Rodent Models. J PHARMACOL EXP THERAP

Daley-Yates et al. Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 ug and fluticasone proprionate 250 ug: Implications of establishing bioequivalence of inhaled products. Clin Therap

Williams et al. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: Two single-dose, open-label, randomized-sequence, crossover studies. Clini Therap

Jenkins et al. Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis. Eur J Clin Pharmacol

Pulido et al. Long-Term Efficacy and Safety of Fosamprenavir plus Ritonavir Versus Lopinavir/Ritonavir in Combination with Abacavir/Lamivudine over 144 Weeks. HIV Clin Trials

Lister et al. Pharmacokinetics, Safety, and Tolerability of Ascending Doses of Sublingual Fentanyl With and Without Naltrexone in Japanese Subjects. J Clin Pharmacol

Hüttner et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers. J Clin Pharmacol

Thomas et al. (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor, Has a Superior Potency and Longer Duration of Action Compared with Other Dipeptidyl Peptidase-4 Inhibitors. J PHARMACOL EXP THERAP

Kassianos. Ambulatory ECG monitoring in primary care. Prim Care Cardiovase J.

Mallal et al. HLA-B*57-1 Screening for Hypersensitivity to Abacavir. New Eng J Med.

Dixon et al. Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects. British Journal of Clinical Pharmacology

Gunthorpe et al. Characterization of SB-705498, a Potent and Selective Vanilloid Receptor-1 (VR1/TRPV1) Antagonist That Inhibits the Capsaicin-, Acid-, and Heat-Mediated Activation of the Receptor. J PHARMACOL EXP THERAP

Flood-Page et al. A Study to Evaluate Safety and Efficacy of Mepolizumab in Patients with Moderate Persistent Asthma. Am J Respir Crit Care Med

McHutchison et al. Eltrombopag for Thrombocytopenia in Patients with Cirrhosis Associated with Hepatitis C. New Eng J Med

Hoen et al. Predictors of Virological Outcome and Safety in Primary HIV Type 1–Infected Patients Initiating Quadruple Antiretroviral Therapy: QUEST GW PROB3005. Clin Infect Dis

Dixon et al. Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects. Br J Clin Pharmacol

Ismail et al. Characterization of the metabolites of alosetron in experimental animals and human. Xenobiotica

Felicia et al. Patterns of asthma-related health care resource use in children treated with montelukast or fluticasone. CURRENT MED RES OPIN

Cockcroft et al. Pulse Pressure Predicts Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus. Am J Hypertens

McEwan et al. Patterns of graft and patient survival following renal transplantation and evaluation of serum creatinine as a predictor of survival: a review of data collected from one clinical centre over 34 years. Current Med Res OpinKinloch–de Loes et al. Impact of Therapeutic Immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. CURRENT MED RES OPIN

Kinloch–de Loes et al. Impact of Therapeutic Immunization on HIV-1 Viremia after Discontinuation of Antiretroviral Therapy Initiated during Acute Infection. J Infect Dis

Hindmarch. A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers. Psychopharmacology

Hindmarch et al. A Double-Blind Study in Healthy Volunteers to Assess the Effects on Sleep of Pregabalin Compared with Alprazolam and Placebo. Sleep

Kempsford et al. Comparison of the systemic pharmacodynamic effects and pharmacokinetics of salmeterol delivered by CFC propellant and non-CFC propellant metered dose inhalers in healthy subjects. Resp Med

Barnett et al. A placebo-controlled crossover study comparing the effects of nateglinide and glibenclamide on postprandial hyperglycaemia and hyperinsulinaemia in patients with type 2 diabetes. Diab, Ob Metab

Gathe et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS

Currie et al. Evaluation of the future supply and demand for blood products in the United Kingdom National Health Service. Transfusion Med

McEwan et al. Evaluating the performance of the Framingham risk equations in a population with diabetes. Diabet Med

Evans et al. Should we routinely measure a proxy for insulin resistance as well as improve our modelling techniques to better predict the likelihood of coronary heart disease in people with type 2 diabetes? For debate. Diab, Ob Metab

Currie et al. The financial costs of hospital care for people with diabetes who have single and multiple macrovascular complications. Diab Res Clin Prac

Currie et al. Comparative estimates of the financial burden to the UK health system of hospital care for people with and without diabetes in the year before death. Diab Res Clin Prac

Wood et al. A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patients. Clin Infect Dis

Vibhagool et al. Triple nucleoside treatment with abacavir plus the lamivudine/ zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy naïve adults: results of a 48-week open-label, equivalence trial (CNA3014). CURRENT MED RES OPIN

MacManus et al GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks. AIDS

Rodriguez-French et al. The NEAT Study: A 48-Week Open-Label Study to Compare the Antiviral Efficacy and Safety of GW433908 Versus Nelfinavir in Antiretroviral Therapy–Naïve HIV-1-Infected Patients. J Acquir Immune Defic Syndr

Prince et al. Phase II Clinical Study of BC-3781, a Pleuromutilin Antibiotic, in Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections. Antimicrobial Agents Chemother

Anderson et al. The effect of nateglinide taken with food on gastric emptying rates in healthy subjects. Clinical Therapeutics

Tilling et al. Parallel decline of CD8+ /CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection. AIDS

Jabs et al. HIV and cytomegalovirus viral load and clinical outcomes in AIDS and cytomegalovirus retinitis patients: Monoclonal Antibody Cytomegalovirus Retinitis Trial. AIDS

Singh et al. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in chronic obstructive pulmonary disease. Br J Clin Pharmacol

Andersson et al. Low Levels of Perforin Expression in CD81 T Lymphocyte Granules in Lymphoid Tissue during Acute Human Immunodeficiency Virus Type 1 Infection. J Infect Dis

Anderson et al. No effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers. J Clin Pharmacol

Standing et al. Changes in referral patterns to cardiac out-patient clinics with ambulatory ECG monitoring in general practice. Br J Cardiol

Cass et al. The bioavailability of the novel nonnucleoside reverse transcriptase inhibitor GW420867X is unaffected by food in healthy male volunteers. J Clin Pharmacol

Goh et al. Study Protocol for the Evaluation of the Potential for Durable Viral Suppression After Quadruple HAART With or Without HIV Vaccination: The QUEST Study. HIV Clin Trials

Lore et al. Accumulation of DC-SIGN+CD40+ dendritic cells with reduced CD80 and CD86 expression in lymphoid tissue during acute HIV-1 infection. AIDS

Mallal et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS

Thomas et al. Brain and CSF entry of the novel nonnucleoside reverse transcriptase inhibitor, GW420867X. NeuroReport

Goh et al. The Quest Trial, a paradigm of HIV collaborative research. Nature Medicine

Purdon. In bed with the enemy. Clin Res Focus

Dove et al. Dual Efficacy of Lamivudine Treatment in Human Immunodeficiency Virus/Hepatitis B Virus–Coinfected Persons in a Randomized, Controlled Study (CAESAR). J Infect Dis

Hardman et al. The future of clinical trials and drug development: 2050. Drugs Context

Eastwood et al. A Randomized Trial of a Composite T2-Biomarker Strategy Adjusting Corticosteroid Treatment in Severe Asthma: A Post Hoc Analysis by Sex J Allergy Clin Immonol.

Quing et al. Blood transcriptomic signature in type-2 biomarker-low severe asthma and asthma control. J Allergy Clin Immunol

Mundy et al. Association for Human Pharmacology in the Pharmaceutical Industry Conference 2022: Impending Change, Innovations and Future Challenges. Front Pharmacol

Efimov et al. Open-label use of an aliphatic polyamine immunomodulator in patients hospitalized with COVID-19. Drugs Context

Kompier et al. Analysis of the safety and immunogenicity profile of an azoximer bromide polymer-adjuvanted subunit influenza vaccine. f1000Research

Busby et al. Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma. ERJ

Diver et al. Relationship between inflammatory status and microbial composition in severe asthma and during exacerbation. Allergy

McDowell et al. Exacerbation Profile and Risk Factors in a Type-2–Low Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation Phenotypes. Am J Resp Crit Care Med

Hardman et al. Changes to working practices in medical communications during the COVID-19 pandemic: Insights from two surveys. Medical Writing

Harrison et al. Impact of the COVID-19 Pandemic on Clinical Trial Conduct: Lessons for the Future. f1000Research

Nar et al. Action of Dipeptidyl Peptidase‐4 Inhibitors on SARS‐CoV‐2 Main Protease. ChemMedChem

Cheriyan et al. Human challenge trials the covid-19 vaccines still have much to teach us Response

Gomez-Cabrero et al. A robust machine learning framework to identify signatures for frailty: a nested case-control study in four aging European cohorts. GeroScience

Efimov et al. The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study. Drugs Context

Hardman et al. Challenges of working from home during the COVID-19 pandemic: A survey to inform working practices. Medical Writing

Heaney, et al. Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial. Lancet Respiratory Medicine

Hardman et al. Corticosteroid optimisation in severe asthma using composite biomarkers to adjust dose versus a symptom/risk-based algorithm E-POSTER Nr 4618

Hardman et al. Ten tips for promoting your research. Cardiovasc Endocrinol Metab

Rengelshausen et al. How to Interpret an Investigator’s Brochure for Meaningful Risk Assessment: Results of an AGAH Discussion Forum.

Tancoš et al. Programmed death ligand 1 protein expression, histological tumour differentiation and intratumoural heterogeneity in pulmonary adenocarcinoma. Pathology

Kahn et al. The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting October 2019: Impending Change, Innovation, and Future Challenges. Front Pharmacol

Rodriguez‐Mañas et al. Effectiveness of a multimodal intervention in functionally impaired older people with type 2 diabetes mellitus. J Cachexia, Sarcopenia Muscle

Breithaupt-Grögler et al. The New First-in-Human EMA Guideline: Disruptive or Constructive? Outcomes From the First EUFEMED Discussion Forum. Front Pharmacol

Hardman et al. European Federation for Exploratory Medicines Development Lyon Conference 2019: The Changing Landscape of Early Medicines Development—Be Prepared. Frontiers Pharmacol

Hanratty et al. A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial. Trials

Van Bortel et al. EUFEMED London Conference 2017: Exploratory Medicines Development: Innovation and Risk Management. Frontiers Pharmacol

Reijntjes et al. The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting 2018: Brexit and Other Challenges in Early Phase Drug Development. Frontiers Pharmacol

Hardman and Serginson. Ready! Aim! Fire! targeting the right medical science journal. J Cardiovasc Endocrinol

Heaney et el. Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK). Thorax

Reijntjes S et al. Bariatric surgery in obese older people: Useful or not? Cardiovasc Endocrinol

Dubrey et al. Sarcoidosis: The links between epidemiology and aetiology. Medical Journal

Rodriguez‐Mañas et al. An evaluation of the effectiveness of a multi-modal intervention in frail and pre-frail older people with type 2 diabetes - the MID-Frail study: Study protocol for a randomised controlled trial. Trials

Hardman and Dubrey. New therapies in the management of type 2 diabetes. Br J Hosp Med

Wierzbicki et al. New therapies to reduce low-density lipoprotein cholesterol. Current Opin in Cardiol

Doyle et al. Midodrine: use and current status in the treatment of hypotension. Br J Cardiol

Dubrey et al. Cardiovascular medication in women and urinary continence. Geriatric Med

Wierzbicki et al. Drugs in development for the management of dyslipidaemia. Future Prescriber

Wierzbicki et al. Inhibition of pre-protein convertase serine kexin-9 (PCSK-9) as a treatment for hyperlipidaemia. Expert Opin Inv Drugs

Wierzbicki et al. New lipid-lowering drugs: An update. Int J Clin Prac

Hardman and Dubrey. Development and potential role of Type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes. Diabetes Ther

Hardman et al. Sodium-Glucose Co-transporter 2 inhibitors: From apple tree to ‘sweet pee’.Current Pharma Design

Wierzbicki et al. Future challenges for microsomal transport protein inhibitors. Curr Vasc Pharmacol

Weirzbicki et al. Clinical aspects of the management of HIV lipodystrophy. Br J Diab Vasc Dis

Wierzbicki et al. HIV lipodystrophy and its metabolic consequences: Implications for clinical practice. Current Med Res Opin

Moore et al. Pharmacokinetics and tolerability of GW420867X, a Nonnucleoside Reverse Transcriptase Inhibitor, following Single Escalating Doses in Healthy Male Volunteers. Journal of Clinical Pharmacology

Wierzbicki et al. The Apolipoprotein E2 Allele Modulates Activity and Maximal Velocity of the Sodium–Lithium Countertransporter. Am J Hypertens

Hardman et al. Correction for the adverse influence of sodium-potassium cotransport on apparent sodium-lithium countertransport activity in human erythrocytes. J Pharmacol Tox Meth.

Falcoz et al. Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers. J Clin Pharmacol

Hardman and Purdon. The cardiological complications associated with HIV infection and acquired immune deficiency syndrome (AIDS). Br J Cardiol

Hardman and Lunnon. The current status of antihypertensive treatments: into the new millennium. Expert Opin in Pharmacother

Moore et al. Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor. Europ J Clin Pharmacol

Moore et al. Pharmacokinetics and tolerability of profile of GW420867X, a non-nucleoside reverse transcriptase inhibitor, following single escalating doses in healthy male volunteers. J Clin Pharmacol

Wierzbicki et al. Relation between sodium–lithium countertransport and hypertriglyceridemia in Type V hyperlipidemia.Am J Hypertens

Hardman et al. Erythrocyte sodium-lithium countertransport in African American women. J Hum Hypertens

Hardman and Noble. Apolipoprotein E gene polymorphism and sodium-lithium countertransport activity. Metabolism

Hardman et al. Sodium-lithium countertransport activity is linked to chromosome 5 in baboons. Hypertens

Dubrey and Hardman. Natriuretic peptides and heart failure: diagnosis, prognosis and treatment. Br J Cardiol

Wierzbicki et al. Effects of lipids in patients with familial hypercholesterolaemia on the kinetics of the sodium-lithium countertransporter. J Hum Hypertens

Hardman et al. Urinary retinol binding protein (RBP) excretion and erythrocyte sodium-lithium countertransport (SLC) activity in a cohort of healthy normotensive subjects. J Hum Hypertens

Hardman et al. Enhanced activity of the sodium lithium countertransporter in patients with cardiac syndrome X: a potential link between cardiac syndrome X and metabolic syndrome X. J Am Coll Cardiol

Wierzbicki et al. Transport of phytanic acid on lipoprotein in Refsum’s disease. J Inherited Metab Dis

Rippin et al. Urine pterin levels in patients with pre-cancerous lesions of the uterine cervix. Clinical Science

Hardman et al. Erythrocte Na+/Li+ countertransport and Na+/K+ -2Cl- co-transport in essential Hypertension

Wierzbicki et al. Na,Li-Countertransport and ethnicity. American Journal of Hypertension

Hardman et al. Erythrocyte sodium lithium countertransport (SLC) activity and retinol binding protein (RBP) in healthy normotensive subjects. Clin Sci

Hardman et al. Urinary retinol binding protein (RBP) excretion and erythrocyte sodium-lithium countertransport (SLC) activity in a cohort of healthy normotensive subjects. J Hum Hyperten

Hardman et al. Characterization of the erythrocyte sodium-lithium countertransporter; limitations and assumptions of traditional and kinetic methodologies. J Memb Biol

Hardman et al. Influence of plasma phytanic acid levels in Refsum’s disease on the behaviour of the erythrocyte membrane sodium-lithium countertransporter. Euro J Clin Inves

Hardman et al. Erythrocyte Na+/Li+ countertransport and Na+/K+ -2Cl- co-transport in essential hypertension. Clin Sci

Hardman et al. Kinetic characteristics of the erythrocyte sodium-lithium countertransporter in black normotensive subjects compared with other ethnic groups. J Hum Hypertens

Hardman and Wierzbicki. Na,Li-countertransport and ethnicity American Journal of Hypertension

Chalkley et al. Reductions in blood lead in school children since the phase-down of the use of lead in petrol. Clinical Science

Chalkley et al. Iron deficiency in a cohort of school children living within the inner-city London area. Clinical Science

Hardman et al. Comparison of traditional and bicarbonate lithium loading methods on the characteristics of the sodium-lithium countertransporter (SLC). Clin Sci

Wierzbicki et al. Transport of phytanic acid on lipoproteins in Refsum’s disease. Clin Sci

Wierzbicki et al. Sodium-lithium countertransport in patients with Refsum’s disease. Clin Sci

Chalkley et al. Effects of exposure to lead and cadmium on metabolism of vitamin D3 in smelter workers. Clin Sci

Hardman et al. Influence of plasma phytanic acid levels in Refsum’s disease on the behaviour of the erythrocyte membrane sodium-lithium countertransporter. Clin Sci

Wierzbicki et al. Triglyceride not insulin resistance principally determines sodium-lithium countertransport activity in patients with hyperchylomicronaemia. Am J Hypertens

Chalkley et al. Benign Hyperbilirubinaemia in Tuvaluan Schoolchildren. Clin Sci

Chalkley et al. Relationship of Mean Cell Volume and Blood Lead in London Schoolchildren at Low Lead Levels. Clin Sci

Hardman et al. Erythrocyte sodium-lithium countertransport (SLC) activity and retinol binding protein (RBP) excretion in healthy normotensive subjects. Clin Sci

Chalkley et al. Blood lead levels and indices of anaemia in London schoolchildren. Clin Sci

Hardman et al. Cation transport in Bartter’s syndrome. J Hypertens